Free shipping on all orders over $ 500

Cilengitide

Cat. No. M2042
Cilengitide Structure
Synonym:

EMD 121974, NSC 707544

Size Price Availability Quantity
5mg USD 130  USD130 In stock
10mg USD 200  USD200 In stock
50mg USD 650  USD650 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. Cilengitide binds to the activities of the αvβ3 and αvβ5 integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. Cilengitide (EMD 121974) could increase systemic RIT efficacy of therapy in a human breast cancer tumor model having mutant p53 and expressing bcl-2. Cilengitide is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors.

Product Citations
Chemical Information
Molecular Weight 588.66
Formula C27H40N8O7
CAS Number 188968-51-6
Solubility (25°C) DMSO: ≥ 45 mg/mL
Storage -20°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Scaringi C, et al. Anticancer Res. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.

[2] Nabors LB, et al. Cancer. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

[3] Burke PA, et al. Cancer Res. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Related Integrin Products
HSDVHK-NH2

HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).

LDV

LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC.

Cyclo(RADfK)

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

Obtustatin

Obtustatin is a non-RGD disintegrin of 41 residues.

Integrin Binding Peptide

Integrin Binding Peptide is derived by fibronectin.

  Catalog
Abmole Inhibitor Catalog




Keywords: Cilengitide, EMD 121974, NSC 707544 supplier, Integrin, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.